|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.99/-1.51
|
企業價值
934.30M
|
資產負債 |
每股賬面淨值
0.97
|
現金流量 |
現金流量率
--
|
損益表 |
收益
145.24M
|
每股收益
3.05
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/01 04:16 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |